# PROCAS: Lifestyle Breast Cancer Prevention Feasibility Study

Submission date	Recruitment status No longer recruiting	[X] Prospectively registered		
26/09/2014		☐ Protocol		
Registration date 26/09/2014	Overall study status Completed	Statistical analysis plan		
		[X] Results		
Last Edited	Condition category	[] Individual participant data		
24/11/2021	Cancer			

#### Plain English summary of protocol

http://www.cancerresearchuk.org/about-cancer/trials/a-study-looking-whether-information-about-risk-affects-whether-women-follow-weight-loss-programme-procas-lifestyle-study

# Contact information

#### Type(s)

Scientific

#### Contact name

Mrs Mary Pegington

#### Contact details

The Nightingale Centre
Wythenshawe Hospital
Southmoor Road
Manchester
United Kingdom
M23 9LT
+44 161 291 4854
mary.pegington@manchester.ac.uk

# Additional identifiers

Protocol serial number 17480

# Study information

#### Scientific Title

PROCAS: Lifestyle Breast Cancer Prevention Feasibility Study: randomised controlled study

#### **Acronym**

**PROCAS** 

#### **Study objectives**

Does personalised information about risk of cardiovascular disease and diabetes enhance uptake and adherence to a weight loss programme amongst women who receive breast cancer risk feedback in the NHS Breast Cancer?

#### Ethics approval required

Old ethics approval format

#### Ethics approval(s)

West Midlands - Solihull Research Ethics Committee, 09/09/2014, ref: 14/WM/1088

#### Study design

Randomised; Interventional; Design type: Prevention

#### Primary study design

Interventional

#### Study type(s)

Quality of life

#### Health condition(s) or problem(s) studied

Topic: Cancer; Subtopic: Breast Cancer; Disease: Breast

#### **Interventions**

172 overweight women currently enrolled on the PROCAS Study will be randomly assigned to a weight loss / lifestyle programme with either:

#### 1. A standard care group (n = 40)

A reminder their individual breast cancer risk and information that weight loss of >5% and lifestyle change can reduce this risk by 25%-30%. They will receive general (not personalised) information on the likely reductions in risk of other diseases with > 5% weight loss/ lifestyle change.

#### 2. An NHS health check group (n = 80)

As above but they will also receive an NHS health check and personalised information on their risk of developing cardiovascular disease and Type 2 diabetes. This group will be informed that weight loss of >5% and lifestyle change can reduce their risk of breast cancer by 25%- 30%, their risk of diabetes by 60% and CVD by 30%.

All participants are seen at baseline, three and six months.

#### **Intervention Type**

Other

#### Phase

Not Applicable

#### Primary outcome(s)

Weight, body fat and fat-free mass are measured at baseline, 3 and 6 months

#### Key secondary outcome(s))

- 1. Biomarkers of CVD (lipids, systolic and diastolic blood pressure), diabetes (HbA1c) are measured at baseline, 3 and 6 months
- 2. Quality of life is measured using the SF-36 questionnaire at baseline, 3 and 6 months
- 3. Health status is measured using the EQ-5D questionnaire at baseline, 3 and 6 months

#### Completion date

01/12/2017

# **Eligibility**

#### Key inclusion criteria

- 1. Attending the NHSBSP aged 47 74 years and part of the PROCAS study
- 2. Women who have previously received feedback of their personalised breast cancer risk by phone / face to face / letter
- 3. BMI ≥25 kg/m2 as breast cancer risk is seen amongst overweight as well as obese women
- 4. Access to and ability to use a telephone and high/moderate-speed internet
- 5. Women in the North, Central and South Manchester Clinical Commissioning Groups who are eligible for NHS health check with Public Health Manchester
- 6. Agree that results of any NHS health checks conducted in the study can be communicated back to their GP. This is a requirement of NHS health checks to allow patients with undiagnosed CVD or diabetes or high risks of these diseases to receive appropriate follow up tests and medical management.

# Participant type(s)

Patient

#### Healthy volunteers allowed

No

#### Age group

Adult

#### Sex

Female

#### Total final enrolment

178

#### Key exclusion criteria

Exclusion criteria as of 03/11/2016:

- 1. Previous diagnosis of cancer, diabetes, CVD or receiving medication for raised cholesterol. Women with previous non-melanoma skin cancer or cervical intra-epithelial neoplasia will be accepted.
- 2. Physical or psychiatric condition which precludes suitability or adherence to a home-based diet and exercise programme
- 3. Current user of hormone replacement therapy (weight affects breast cancer risk amongst non-HRT users only)

- 4. Advanced renal failure and attending a pre dialysis clinic.
- 5. Currently successfully following a diet and/or exercise plan and have lost more than 2 lb (1 kg) of weight in the last 2 weeks

#### Original exclusion criteria:

- 1. Previous diagnosis of cancer, diabetes, CVD or receiving medication for raised cholesterol
- 2. Physical or psychiatric condition which precludes suitability or adherence to a home-based diet and exercise programme
- 3. Current user of hormone replacement therapy (weight affects breast cancer risk amongst non-HRT users only)

#### Date of first enrolment

01/10/2014

#### Date of final enrolment

01/12/2016

# Locations

#### Countries of recruitment

**United Kingdom** 

England

# Study participating centre Wythenshawe Hospital

Nightingale Centre Southmoor Road Manchester United Kingdom M23 9LT

# Sponsor information

#### Organisation

University Hospital of South Manchester NHS Foundation Trust

#### **ROR**

https://ror.org/00he80998

# Funder(s)

# Funder type

Charity

#### Funder Name

Prevent Breast Cancer Limited

# **Results and Publications**

#### Individual participant data (IPD) sharing plan

The current data sharing plans for the current study are unknown and will be made available at a later date.

#### IPD sharing plan summary

Data sharing statement to be made available at a later date

#### **Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	04/12/2019	05/06/2020	Yes	No
HRA research summary			28/06/2023	No	No
Other publications	reply to comment	01/03/2020	05/06/2020	Yes	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes
Plain English results		24/11/2021	24/11/2021	No	Yes